Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation

Clin Neurol Neurosurg. 2019 Jun;181:64-66. doi: 10.1016/j.clineuro.2019.03.020. Epub 2019 Mar 28.

Abstract

The target brain binding site of levetiracetam (LEV) is synaptic vesicle glycoprotein 2A (SV2A). Up to now, only a homozygous pathogenic SV2A gene mutation was reported in human. We now report a novel heterozygous pathogenic SV2A gene mutation both in a girl and her mother result in epilepsy and poor response to LEV. Furthermore, the girl developed a new seizure type after using LEV. Our report had a clinical relevance that LEV could potentially produce contradictory efficacy in patients with SV2A gene mutation. If patients' seizures became exacerbated while using LEV, SV2A gene testing is recommended.

Keywords: Levetiracetam; Myoclonus; Novel mutation; SV2A; Spasm.

Publication types

  • Case Reports

MeSH terms

  • Anticonvulsants / therapeutic use
  • Brain / metabolism
  • Child, Preschool
  • Female
  • Humans
  • Levetiracetam / adverse effects*
  • Membrane Glycoproteins / genetics*
  • Mutation / genetics*
  • Nerve Tissue Proteins / genetics*
  • Piracetam / therapeutic use
  • Seizures / chemically induced
  • Seizures / genetics*

Substances

  • Anticonvulsants
  • Membrane Glycoproteins
  • Nerve Tissue Proteins
  • SV2A protein, human
  • Levetiracetam
  • Piracetam